Amylyx Pharmaceuticals (AMLX) EPS (Weighted Average and Diluted): 2021-2025
Historic EPS (Weighted Average and Diluted) for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Sep 2025 value amounting to -$0.37.
- Amylyx Pharmaceuticals' EPS (Weighted Average and Diluted) rose 65.42% to -$0.37 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.79, marking a year-over-year increase of 53.14%. This contributed to the annual value of -$4.43 for FY2024, which is 732.86% down from last year.
- As of Q3 2025, Amylyx Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.37, which was up 19.57% from -$0.46 recorded in Q2 2025.
- Amylyx Pharmaceuticals' EPS (Weighted Average and Diluted)'s 5-year high stood at $0.31 during Q2 2023, with a 5-year trough of -$4.15 in Q4 2021.
- Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$0.42 (2025), whereas its average is -$0.45.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first spiked by 133.33% in 2023, then tumbled by 8,850.00% in 2024.
- Quarterly analysis of 5 years shows Amylyx Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$4.15 in 2021, then surged by 85.06% to -$0.62 in 2022, then spiked by 111.29% to $0.07 in 2023, then plummeted by 871.43% to -$0.54 in 2024, then surged by 65.42% to -$0.37 in 2025.
- Its last three reported values are -$0.37 in Q3 2025, -$0.46 for Q2 2025, and -$0.42 during Q1 2025.